Boston Scientific Announces Results for First Quarter 2024
PRNewswire (Wed, 24-Apr 6:30 AM ET)
Wells Fargo Sticks to Its Hold Rating for Axonics Modulation Technologies (AXNX)
TipRanks (Tue, 23-Apr 9:38 AM ET)
Axonics Stockholders Approve Merger Agreement with Boston Scientific
Business Wire (Fri, 22-Mar 4:01 PM ET)
Axonics Provides Update on Inter Partes Review Proceedings
Business Wire (Thu, 21-Mar 4:54 PM ET)
Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System
Business Wire (Thu, 14-Mar 6:00 AM ET)
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates MDC, AXNX, CPE
Globe Newswire (Sat, 2-Mar 10:45 AM ET)
Axonics Responds to ITC Action by Medtronic
Business Wire (Thu, 29-Feb 4:01 PM ET)
Axonics Reports Fourth Quarter and Fiscal Year 2023 Financial Results
Business Wire (Wed, 28-Feb 4:01 PM ET)
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AXNX, KAMN, JNPR, AVRO
Globe Newswire (Wed, 28-Feb 12:00 AM ET)
Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is predominantly used to treat patients with overactive bladder, fecal incontinence, and urinary retention. Geographically, the company generates majority of its revenue from United States and rest from International markets.
Axonics trades on the NASDAQ stock market under the symbol AXNX.
As of April 25, 2024, AXNX stock price declined to $66.61 with 169,143 million shares trading.
AXNX has a beta of 1.38, meaning it tends to be more sensitive to market movements. AXNX has a correlation of 0.19 to the broad based SPY ETF.
AXNX has a market cap of $3.40 billion. This is considered a Mid Cap stock.
Last quarter Axonics reported $110 million in Revenue and $.13 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.07.
In the last 3 years, AXNX stock traded as high as $79.92 and as low as $38.41.
The top ETF exchange traded funds that AXNX belongs to (by Net Assets): VTI, VB, IWM, VXF, VBK.
AXNX has underperformed the market in the last year with a return of +10.9%, while the SPY ETF gained +23.2%. In the last 3 month period, AXNX fell short of the market, returning -2.1%, while SPY returned +3.7%. However, in the most recent 2 weeks AXNX has outperformed the stock market by returning -1.6%, while SPY returned -2.4%.
AXNX support price is $66.17 and resistance is $67.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AXNX stock will trade within this expected range on the day.